Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population
Treatment outcomes between the two types of CDK4/6i did not differ significantly, indicating the safety and efficacy of CDK4/6i for the Asian population. Ribociclib and palbociclib showed similar efficacy in PFS in the real-world setting.
Authors
- Pei‐Ju Lien (ORCID: https://orcid.org/0000-0003-4644-1533)
- Yen-Jen Chen
- Jiun‐I Lai (ORCID: https://orcid.org/0000-0002-8233-5466)
- Chin-Jung Feng
- Bo-Fang Chen (ORCID: https://orcid.org/0000-0002-4053-5232)
- Han-Fang Cheng
- Yen‐Shu Lin
- Ta-Chung Chao
- Yi-Fang Tsai
- Ling-Ming Tseng
- Chun-Yu Liu
- Chi-Cheng Huang
Institutions
- National Yang Ming Chiao Tung University (TW)
- National Taipei University of Nursing and Health Science (TW)
- Taipei Veterans General Hospital (TW)
Publication Details
- Journal
- Clinical and Experimental Medicine
- Published
- 2024-08-12
- DOI
- https://doi.org/10.1007/s10238-024-01458-1
- Citations
- 11
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 4.61
Funders
- Taiwan Clinical Oncology Research Foundation
- Taipei Veterans General Hospital